Skip to main content

Advertisement

ADVERTISEMENT

Multiple Sclerosis News

News
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care
News
10/29/2024
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the...
10/29/2024
First Report Managed Care

Advertisement

News
10/28/2024
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the...
10/28/2024
First Report Managed Care
News
10/25/2024
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of...
10/25/2024
First Report Managed Care
News
10/25/2024
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study...
10/25/2024
First Report Managed Care

Advertisement

News
09/19/2024
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not...
09/19/2024
First Report Managed Care
News
08/16/2024
Current evidence regarding the role of brain-derived neurotrophic factor (BDNF) in patients with multiple sclerosis (MS) is largely inconclusive, according to a review article published in Frontiers in Neurology.
Current evidence regarding the role of brain-derived neurotrophic factor (BDNF) in patients with multiple sclerosis (MS) is largely inconclusive, according to a review article published in Frontiers in Neurology.
Current evidence regarding the...
08/16/2024
First Report Managed Care
News
07/15/2024
Focusing solely on relapse rates and magnetic resonance imaging (MRI) lesion activity to track disease progression in patients with early multiple sclerosis (MS) may miss indicators of subclinical disease activity, with important implications...
Focusing solely on relapse rates and magnetic resonance imaging (MRI) lesion activity to track disease progression in patients with early multiple sclerosis (MS) may miss indicators of subclinical disease activity, with important implications...
Focusing solely on relapse rates...
07/15/2024
First Report Managed Care

Advertisement

News
06/14/2024
Testing cellular response to Epstein-Barr virus nuclear antigen-1 (EBNA-1) may benefit patients with multiple sclerosis (MS), suggests a study published in the journal Neurology: Neuroimmunology & Neuroinflammation.
Testing cellular response to Epstein-Barr virus nuclear antigen-1 (EBNA-1) may benefit patients with multiple sclerosis (MS), suggests a study published in the journal Neurology: Neuroimmunology & Neuroinflammation.
Testing cellular response to...
06/14/2024
First Report Managed Care

Advertisement